Retatrutide, a new dual activator of the GLP-1 receptor and glucose-dependent secreted polypeptide (GIP) receptor , is exhibiting promising results in preliminary clinical trials . Recent research https://mypresspage.com/story6465065/retatrutide-emerging-investigations-and-projected-clinical-uses